Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/53782
Title: PRECLINICAL INVESTIGATION OF 3-DEAZANEPLANOCIN A (DZNEP) ANALOG 1-3 AS A NEW EPIGENETIC ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA (AML) AND METASTATIC BREAST CANCER
Authors: JIANG XIA
Keywords: EPIGENETIC, ANTICANCER, AML, METASTATIC, BREAST, CANCER
Issue Date: 17-Oct-2013
Source: JIANG XIA (2013-10-17). PRECLINICAL INVESTIGATION OF 3-DEAZANEPLANOCIN A (DZNEP) ANALOG 1-3 AS A NEW EPIGENETIC ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA (AML) AND METASTATIC BREAST CANCER. ScholarBank@NUS Repository.
Abstract: We have recently reported that 3-Deazaneplanocin A (DZNep) is a histone methylation inhibitor that can deplete oncogenic PRC2 complex and induce strong apoptosis in cancer cells but not in normal cells. To develop DZNep analogues toward druggability, we tested over 300 DZNep analogues for structure and activity relationship (SAR) analysis. This study led to one candidate compound named as I-3 that has shown promising result. The aim of my project is to characterize the anti-cancer effects of I-3 in acute myeloid leukemia (AML) and aggressive breast cancer. We found that I-3 targets not only bulk leukemic cells but also leukemia stem cells in AML. Moreover, I-3 in combination with HDAC inhibitor SAHA inhibits the metastasis property of MDA-MB-231 cells both in vitro and in vivo in part through E-cadherin induction. Our results demonstrated I-3 as a novel chromatin remodeling compound may constitute a novel potential for cancer therapy.
URI: http://scholarbank.nus.edu.sg/handle/10635/53782
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
JiangX PhD thesis.pdf14.35 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

69
checked on Dec 11, 2017

Download(s)

42
checked on Dec 11, 2017

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.